NCT06183645
Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibility.
Recruiting · Not specified · Centre Hospitalier Universitaire de Liege · registry updated 2025-02-12
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
ActiCIDP is a monocentric academic study. Patients with Chronic inflammatory demyelinating polyradiculoneuritis may be included on a voluntary basis. The investigators plan to include a group of approximately 40 patients with CIDP. The investigators have planned to assess patient every three months for a year. After each visit, participants will wear Actimyo for one month daily.
Inclusion
- Diagnosed with CIDP or possible CIDP based on 2021 EAN/PNS criteria2.
- Treated with IVIg (≤1g/kg/3-8week)
- Clinically Stable disease for 3 months (according to treating physician opinion).
- No treatment withdrawal failure within 1 year
- Age over 18 years
Exclusion
- Significant cognitive or communication disorders
- Surgery or serious traumatic injury ≤ 6 months
- Non ambulant patient
- Current participation to a therapeutic trial
- Anti-myeline antibodies (anti-MAG) positive or nodo-paranodopathy
- Other autoimmune disease that requires Corticosteroids, IVIg, Plasma Exchange treatment